FDA Approves Tecentriq Plus Chemotherapy for Stage III dMMR Colon Cancer
The FDA on October 9 approved Roche's Tecentriq (atezolizumab) with fluoropyrimidine and oxaliplatin chemotherapy as adjuvant treatment for stage III mismatch repair-deficient (dMMR) colon cancer, the drug's 12th U.S. indication. The pivotal trial showed the combination cut the risk of recurrence or death by about half. Eligibility must be assessed by an oncologist.
(Source: FDA and Roche announcements)
Source: FDA and Roche announcements
Published by GSM · USA (original Chinese edition)
Photo: The U.S. Food and Drug Administration, Public domain (Wikimedia Commons)
